As previously reported, Evercore ISI analyst Joshua Schimmer downgraded Crispr Therapeutics (CRSP) to In Line from Outperform with a price target of $52, down from $85. Schimmer noted that the stock's current market value equals as much as four of its closest peers - namely Intellia Therapeutics (NTLA), Editas Medicine (EDIT), Sangamo (SGMO) and Precision BioSciences (DTIL) - combined, telling investors "We're not sure NTLA + EDIT + SGMO + DTIL should = CRSP." Additionally, Crispr "has a long way to go" for its gene editing results to truly compare with Bluebird Bio's (BLUE) LentiGlobin, according to Schimmer, who also upgraded Bluebird Bio to Outperform from In Line this morning.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Intra-Cellular Therapies... To see the rest of the story go to thefly.com. See Story Here